• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $COLL

    Collegium Pharmaceutical Inc.

    Subscribe to $COLL
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: collegiumpharma.com

    Peers

    $ACRX

    Recent Analyst Ratings for Collegium Pharmaceutical Inc.

    DatePrice TargetRatingAnalyst
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    5/2/2023$30.00Buy
    Jefferies
    8/8/2022Buy → Neutral
    H.C. Wainwright
    2/22/2022$36.00 → $42.00Overweight
    Piper Sandler
    See more ratings

    Collegium Pharmaceutical Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

      SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 5:13:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 4:30:24 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/14/24 12:04:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/12/24 6:06:37 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/10/23 4:00:19 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/14/22 12:04:31 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/14/22 9:40:24 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/14/22 8:41:35 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/9/22 3:43:30 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/16/21 3:40:59 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Collegium Pharmaceutical Inc. Financials

    Live finance-specific insights

    See more
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

      STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Compa

      4/24/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

      – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON,

      2/27/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q4 2024 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available fo

      2/13/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Record Third Quarter 2024 Financial Results

      – Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million – – Achieved Q3'24 GAAP Net Income of $9.3 Million – – Delivered Record Q3'24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year – – Closed Acquisition of Ironshore Therapeutics, Establishing Presence in Neurology (ADHD) – – Appointed Vikram Karnani as Chief Executive Officer of Collegium – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company commit

      11/7/24 4:02:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

      STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q3 2024 Earnings Call." An audio webcast will

      10/24/24 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Completes Acquisition of Ironshore Therapeutics

      – Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has completed the acquisition of Ironshore Therapeutics Inc., a privately held company that markets and distributes Jornay PM (methy

      9/4/24 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Second Quarter 2024 Financial Results

      – Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively –        – Achieved Q2'24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2'24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3'24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurology (ADHD) – – Reaffirmed Full-Year 2024 Guidance for the Current Business – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

      8/8/24 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways announces second quarter 2024 financial results and business highlights

      Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2024 and an update on recent business progress. "As we continue to

      8/1/24 6:30:00 AM ET
      $CMPS
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

      – Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology (ADHD) – – H1'24 Jornay PM Prescriptions Grew 32% Year-over-Year – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition Funded by Collegium's Cash on Hand and New Five-Year Financing with Significantly Improved Terms – – Collegium Estimates Q2'24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024 Financial Guidance for the Current Business – – Conference Call Scheduled for Today at 8:30 a.m. ET – STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) --

      7/29/24 6:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Collegium Pharmaceutical Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Financial Officer Tupper Colleen sold $228,250 worth of shares (7,602 units at $30.02), decreasing direct ownership by 5% to 156,667 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/24/25 5:06:10 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Commercial Officer Dreyer Scott sold $624,794 worth of shares (20,808 units at $30.03), decreasing direct ownership by 17% to 103,613 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/24/25 5:05:13 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & General Counsel Dieter David was granted 68,449 shares (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/19/25 4:36:33 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Dieter David

      3 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/19/25 4:34:49 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: EVP & Chief Commercial Officer Dreyer Scott sold $461,672 worth of shares (15,387 units at $30.00), decreasing direct ownership by 11% to 126,676 units (SEC Form 4)

      4/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/18/25 7:18:19 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Financial Officer Tupper Colleen sold $29,313 worth of shares (977 units at $30.00), decreasing direct ownership by 0.59% to 164,269 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/18/25 5:35:14 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Commercial Officer Dreyer Scott sold $67,661 worth of shares (2,255 units at $30.00), decreasing direct ownership by 2% to 124,421 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/18/25 5:34:13 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Commercial Officer Dreyer Scott sold $461,672 worth of shares (15,387 units at $30.00), decreasing direct ownership by 11% to 126,676 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/13/25 4:50:14 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Financial Officer Tupper Colleen sold $313,413 worth of shares (10,445 units at $30.01), decreasing direct ownership by 6% to 165,246 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/13/25 4:49:26 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Financial Officer Tupper Colleen sold $103,591 worth of shares (3,453 units at $30.00), decreasing direct ownership by 2% to 175,691 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/10/25 4:02:15 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Collegium Pharmaceutical Inc. SEC Filings

    See more

    Collegium Pharmaceutical Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 10-Q filed by Collegium Pharmaceutical Inc.

      10-Q - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/8/25 4:03:27 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/8/25 4:01:22 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.

      SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      5/2/25 10:33:56 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Collegium Pharmaceutical Inc.

      DEFA14A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      3/28/25 4:12:43 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Collegium Pharmaceutical Inc.

      DEF 14A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      3/28/25 4:01:29 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Collegium Pharmaceutical Inc.

      144 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      3/20/25 4:32:02 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update, Other Events

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      3/17/25 7:05:27 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Collegium Pharmaceutical Inc.

      S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      3/6/25 4:05:58 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Collegium Pharmaceutical Inc.

      10-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      2/27/25 4:03:06 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      2/27/25 4:01:24 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

      STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Compa

      4/24/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

      STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified

      4/1/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

      STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled "Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids" has been selected as one of the top abstracts. This distinction includes recognition in AAPM's Pain Medicine Journal, where the abstract will also be published. "We are excited to p

      3/27/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces Updates to its Board of Directors and Executive Leadership Team

             – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

      3/17/25 7:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

      STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025. "Collegium is pleased to present real-world data at NAPNAP as part of our commitment to providing differentiated medicines that help to improve t

      3/10/25 6:57:14 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Participate in Upcoming Investor Conferences

      STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare ConferenceTuesday, March 11, 2025 Jefferies Biotech on the Beach SummitWednesday, March 12, 2025 Barclays 27th Annual Global Healthcare ConferenceThursday, March 13, 2025 About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and rec

      3/4/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

      – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON,

      2/27/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q4 2024 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available fo

      2/13/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Collegium Pharmaceutical Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Collegium Pharmaceutical upgraded by Needham with a new price target

      Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

      1/10/25 8:00:15 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

      7/30/24 6:32:12 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by Jefferies with a new price target

      Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously

      6/7/24 7:29:08 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical downgraded by Needham

      Needham downgraded Collegium Pharmaceutical from Buy to Hold

      5/10/24 7:57:08 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Collegium Pharmaceutical from Overweight to Neutral and set a new price target of $39.00

      5/10/24 7:31:41 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical downgraded by Jefferies with a new price target

      Jefferies downgraded Collegium Pharmaceutical from Buy to Hold and set a new price target of $37.00 from $30.00 previously

      1/4/24 8:13:39 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Collegium Pharmaceutical with a new price target

      Needham reiterated coverage of Collegium Pharmaceutical with a rating of Buy and set a new price target of $36.00 from $35.00 previously

      8/25/23 7:32:42 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Collegium Pharmaceutical with a new price target

      Jefferies resumed coverage of Collegium Pharmaceutical with a rating of Buy and set a new price target of $30.00

      5/2/23 9:03:43 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Collegium Pharmaceutical from Buy to Neutral

      8/8/22 7:23:08 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Collegium Pharmaceutical with a new price target

      Piper Sandler reiterated coverage of Collegium Pharmaceutical with a rating of Overweight and set a new price target of $42.00 from $36.00 previously

      2/22/22 6:25:59 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Collegium Pharmaceutical Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces Updates to its Board of Directors and Executive Leadership Team

             – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

      3/17/25 7:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Appoints Nancy S. Lurker to its Board of Directors

      STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

      2/5/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Appoints Vikram Karnani as Chief Executive Officer

      STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that Vikram Karnani has been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Directors effective November 12, 2024. Michael Heffernan, who has served as Interim President and CEO since May 2024, will remain Chairman of the Board. Mr. Karnani has more than 15 years of leadership experience in the life sciences industry. Over the course of nearly a decade at Horizon Therapeutics, Mr. Karnani he

      11/7/24 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces CEO Transition

      – Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that effective May 24, 2024, Joe Ciaffoni will step down as President and Chief Executive Officer (CEO) of the Company. Mr. Ciaffoni will serve as a member of the Board of Directors of the Company until the

      5/9/24 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Appoints Neil McFarlane to its Board of Directors

      STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. "Collegium is delighted to welcome Neil to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Neil's track record of successful leadership and industry experience will be tremendously valuable for the Company. We are confident that Collegium will benefit from his insights, and we look forward to Neil's meaningful contributions to our Board of Directors." "This is a very important and exci

      4/6/22 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Record Quarterly Revenue of $87.7 Million

      – Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta® Franchise and Adjusted EBITDA 2021 Guidance Range Raised – – Colleen Tupper Appointed as Next CFO; Paul Brannelly will be Leaving the Company to Pursue Other Opportunities – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update. The company also announced the appointme

      5/6/21 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care